Skip to content

Efficacy of an Arabic Articulatory Error Remediation Software Program in Patients With Velopharyngeal Valve Dysfunction:

Formulatin and Application of a Remediation Software Porgram for Correction of Articulatory Errors in Patients With Velopfaryngeal Dysfunction

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04392817
Enrollment
40
Registered
2020-05-19
Start date
2018-01-02
Completion date
2019-02-09
Last updated
2020-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Articulation Disorders, Hypernasality Syndrome Due to Velopharyngeal Weakness, Velopharyngeal Insufficiency

Keywords

Velopharyngeal dysfunction Hypernasality

Brief summary

To develop a remediation software program that is specific for correcting speech errors in patients with velopharyngeal dysfunction in the Arabic language and test its efficacy, on one group comparing pre and post results

Detailed description

The study was carried on 40 patients having articulation errors in cases of velopharyngeal valve dysfunction attending the unit of phoniatrics, otorhinolaryngology department, Alexandria University. The patients met the specified inclusion and exclusion criteria. The patient underwent pre intervention evaluation and 3 parameters were chosen to compare efficacy of the program before and after therapy. these include auditory perceptual assessment of speech, nasometer test and articulation test. The patient underwent the remediation software program as individual sessions. then after finishing the therapy, the patients underwent post therapeutic evaluation with the 3 specified criteria Statistical analysis Was carried out using SPSS statistics software version 23. Quantitative data were tested for normality using the Kolmogorov-Smirnov test. The variables which were normally distributed were described by Mean± SD. The variables which were not normally distributed, were described by median (Min-Max). Qualitative data were expressed by numbers and percentages. The results were calculated at a level of significance of 5% or less.

Interventions

BEHAVIORALArabic Articulatory Error Remediation software program

A speech therapy computerized intervention

Sponsors

Alaa Mamdouh
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

a quasi experimental study comparing pre to post therapy intervention in one group

Eligibility

Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* clinically presented by articulation errors due to velopharyngeal dysfunction * Age of 5 years and above with * must have normal hearing and vision.

Exclusion criteria

* Unrepaired cleft palate. * Large palatal fistula. * Brain damage and intellectual disability.

Design outcomes

Primary

MeasureTime frameDescription
change in Arabic articulation testbase line( pre -intervention)a qualitative test that define presence or absence of articulation errors
change in naso meter valuespre interventiona device that measure nasalance score as a ratio expressed in percentage between nasal sound energy to nasal plus oral sound in patients pre and post intervention for quantitaive assesment of nasal air emission and nasal tone where the lower values mean beteer results
change in Auditory perceptual assessment of speechpre interventionA qualitative scale of patient speech : 5 grade from 0( not present) to 4 (sever)

Secondary

MeasureTime frameDescription
effect of the age factor on nasometer values after interventionimmediately after interventionstatistical tests for correlation
effect of the age factor on auditory perceptual assessment after interventionimmediately after interventionstatistical tests for correlation
effect of the surgical repair on the nasometer values after interventionimmediately after interventioncomparison between two groups

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026